跳至主要内容

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists

Author:Martyna Szpakowska, Max Meyrath, Nathan Reynders, Manuel Counson, Julien Hanson, Jan Steyaert, Andy Chevigné   《Biochemical Pharmacology》


ABSTRACTS
The atypical chemokine receptor ACKR3/CXCR7 plays crucial roles in numerous physiological processes but also in viral infection and cancer. ACKR3 shows strong propensity for activation and, unlike classical chemokine receptors, can respond to chemokines from both the CXC and CC families as well as to the endogenous peptides BAM22 and adrenomedullin. Moreover, despite belonging to the G protein coupled receptor family, its function appears to be mainly dependent on β-arrestin. ACKR3 has also been shown to continuously cycle between the plasma membrane and the endosomal compartments, suggesting a possible role as a scavenging receptor. So far, the molecular basis accounting for these atypical binding and signalling properties remains elusive. Noteworthy, ACKR3 extracellular domains bear three disulphide bridges. Two of them lie on top of the two main binding subpockets and are conserved among chemokine receptors, and one, specific to ACKR3, forms an intra-N terminus four-residue-loop of so far unknown function. Here, by mutational and functional studies, we examined the impact of the different disulphide bridges for ACKR3 folding, ligand binding and activation. We showed that, in contrast to most classical chemokine receptors, none of the extracellular disulphide bridges was essential for ACKR3 function. However, the disruption of the unique ACKR3 N-terminal loop drastically reduced the binding of CC chemokines whereas it only had a mild impact on CXC chemokine binding. Mutagenesis also uncovered that chemokine and endogenous non-chemokine ligands interact and activate ACKR3 according to distinct binding modes characterized by different transmembrane domain subpocket occupancy and N-terminal loop contribution, with BAM22 mimicking the binding mode of CC chemokine N terminus.

Graphical abstract


KEY WORDS
Chemokine receptor; CXCR7; ACKR3; CXCR4; BAM22; CXCL12; Adrenomedulli
SCREENSHOT

RELATED PRODUCTS
 SSS scrbld (1-PPYDVISSMLKDSISNENFVSLPNGPSDTVHMSWDNFMDS-40)
CHAINING
https://www.sciencedirect.com/science/article/abs/pii/S0006295218300960

评论

此博客中的热门博文

CAS:198483-36-2|Cholecystokinin Octapeptide (1-6) (desulfated)|DYMGWM

Contact: Liven Qian(钱叶华)-Custom Peptide Mobile: 13761298676(微信) Email:cps037@chinapeptides.net QQ:2880526724 ChinaPeptides Co., Ltd./强耀生物科技有限公司 Name Cholecystokinin Octapeptide (1-6) (desulfated) Code [198483-36-2] The alias Cholecystokinin Octapeptide (1-6) (desulfated) Sequence (single letter abbreviation) DYMGWM Sequence (three-letter abbreviation) Asp-Tyr-Met-Gly-Trp-Met A basic description solubility The molecular weight 801.94 Chemical formula C36H47N7O10S2 The purity 80%,90%,95%,98%,99% Weight 1mg,5mg,10mg,50mg,100mg,1g Storage conditions Store at -20°C. Keep tightly closed. Store in a cool dry place.

Mitochondria Targeted Peptide Attenuates Mitochondrial Dysfunction, Controls Inflammation and Protects Against Spinal Cord Injury-Induced Lung Injury

文献作者:Zhu L.-L. · Li M.-Q. · He F. · Zhou S.-B. · Jiang W.     《Cellular Physiology and Biochemistry》 ABSTRACTS Background/Aims:   Spinal cord injury (SCI) is a common and devastating disease, which results in systemic inflammatory response syndrome and secondary lung injury. Mitochondrial dysfunction and inflammation are closely related to lung injury in diverse disease models. No studies have demonstrated the effects of mitochondrial targeted peptide SS-31 in a mouse model of SCI-induced lung injury.  Methods:   Immediately after injury, mice in the treatment groups received a daily, single-dose intraperitoneal injection of SS-31 and for the next 2 days. The sham and SCI groups also received a daily single dose of vehicle (DMSO and 0.9% NaCl, 1: 3). The lung tissue of mice was examined after SCI, and tissue damage, apoptosis, inflammation, and mitochondrial dysfunction were recorded.  Results:   SS-31 treatment attenuated lung edema ...

CAS:83651-90-5|α-CGRP (mouse, rat)|SCNTATCVTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH2

Contact: Liven Qian(钱叶华)-Custom Peptide Mobile: 13761298676(微信) Email:cps037@chinapeptides.net QQ:2880526724 ChinaPeptides Co., Ltd./强耀生物科技有限公司 Name α-CGRP (mouse, rat) Code [83651-90-5] The alias α-CGRP (mouse, rat) Sequence (single letter abbreviation) SCNTATCVTHRLAGLLSRSGGVVK DNFV PTNVGSEAF-NH2 Sequence (three-letter abbreviation) Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 A basic description solubility The molecular weight Chemical formula The purity 80%,90%,95%,98%,99% Weight 1mg,5mg,10mg,50mg,100mg,1g Storage conditions Store at -20°C. Keep tightly closed. Store in a cool dry place. Number of Residues: 37 1-Letter Code: SCNTATCVTHRLAGLLSRSGGVVK DNFVPTNVGSEAF-NH2 3-Letter Code: Ser-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asp-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 Molecular ...